MAT vs REGN · P/E 13, rev $5.38B vs P/E 14, rev $14.34B
Mattel Inc (MAT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Mattel Inc (MAT) is a leisure company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported MAT revenue for 2024-12-31 was $5.38B. Net income was $541.8M. Revenue was down 1.1% from 2023-12-31 to 2024-12-31. MAT currently screens at market cap $6.53B and trailing P/E 13.1.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
MAT currently screens at market cap $6.53B and trailing P/E 13.1. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the MAT and REGN stock pages for the full models.
Not investment advice.